Unshackled Ventures — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway.
BiotechHealthtechAustin, US
Anand Parikh(Executive Officer, Director, Promoter)inOliver Maddocks(Executive Officer, Director)inChristopher W. Gerry(President and General Counsel)
BoardAlex Morgan(Director)inJayson Dallas(Director)Robert Gould(Director)
Co-investorsAble PartnersAgFunderAtacama VenturesCota CapitalFuture VenturesiSelect Fund+7 more
Apolink provides on-demand satellite communications infrastructure, enabling real-time telemetry and command links for space operators managing satellites for applications including disaster response, wildfire detection, and intelligence gathering.
Advanced ManufacturingDeep TechEnterprise SoftwareSpace TechSan Francisco, US
Onkar Batra(CEO)inOnkar Singh Batra(Founder)Geffen Avraham(CTO)Emily Karlzen(Head of Ops)
Co-investorsMK Venture CapitalRebel FundY Combinator1802 Ventures468 CapitalEMERGENT VENTURES+8 more
Dosen is a workforce capability platform that lets business leaders define role standards from a company's own knowledge, then train employees and track whether those standards are met.
AI & Machine LearningEdTechHR Tech
Ronan Wall(Founder)in
Co-investorsFuel Ventures
PolyGone develops a patented passive filtration media and systems to intercept and recover sub-millimeter microplastics from water environments such as rivers, reservoirs, and wastewater treatment channels.
CleantechClimate TechHardwareKearny, US
Nathaniel Banks(Executive Officer, Director)inYidian Liu(Founder)in
BoardJulie Maples(Director)in
Co-investorsTech Council Ventures10X CapitalFYRFLY Venture PartnersGolden SeedsINTERSTATE FUSION VENTURESLowercarbon Capital+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
somi
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




















